[go: up one dir, main page]

CY1124523T1 - Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης - Google Patents

Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης

Info

Publication number
CY1124523T1
CY1124523T1 CY20211100407T CY211100407T CY1124523T1 CY 1124523 T1 CY1124523 T1 CY 1124523T1 CY 20211100407 T CY20211100407 T CY 20211100407T CY 211100407 T CY211100407 T CY 211100407T CY 1124523 T1 CY1124523 T1 CY 1124523T1
Authority
CY
Cyprus
Prior art keywords
methyl
preparation
aminosulfonyl
thiazol
pyridinyl
Prior art date
Application number
CY20211100407T
Other languages
English (en)
Inventor
Yogeshwar BACHHAV
Wilfried Schwab
Alexander Birkmann
Kurt Voegtli
Original Assignee
Aicuris Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57421711&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124523(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aicuris Gmbh & Co. Kg filed Critical Aicuris Gmbh & Co. Kg
Publication of CY1124523T1 publication Critical patent/CY1124523T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται στο πεδίο των αντι-ιικών δραστικών παραγόντων, ιδιαίτερα της ημιένυδρης μορφής ελεύθερης βάσης Ν-[5-(αμινοσουλφονυλ1)-4-μεθυλ-1,3-θειαζολ-2-υλ]-Ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ακεταμιδίου, καθώς και σε μεθόδους για την παρασκευή τους. Η παρούσα εφεύρεση αναφέρεται, επίσης, στη χρήση της παραπάνω ένωσης για τη θεραπεία λοιμώξεων από τον ιό του έρπητα και στην παρασκευή φαρμακευτικών ουσιών, οι οποίες περιλαμβάνουν την εν λόγω ένωση.
CY20211100407T 2016-11-28 2021-05-13 Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης CY1124523T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16200967 2016-11-28
PCT/EP2017/080653 WO2018096170A1 (en) 2016-11-28 2017-11-28 N-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)-phenyl]-acetamide free base hemihydrate, methods of manufacture and uses thereof

Publications (1)

Publication Number Publication Date
CY1124523T1 true CY1124523T1 (el) 2022-07-22

Family

ID=57421711

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100407T CY1124523T1 (el) 2016-11-28 2021-05-13 Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης

Country Status (22)

Country Link
US (3) US11021474B2 (el)
EP (3) EP4201934A1 (el)
JP (2) JP6978501B2 (el)
KR (2) KR102622289B1 (el)
CN (1) CN109996798B (el)
AR (1) AR110249A1 (el)
AU (3) AU2017365632B2 (el)
CA (1) CA3045059A1 (el)
CY (1) CY1124523T1 (el)
DK (2) DK3544976T3 (el)
ES (2) ES2941390T3 (el)
HR (1) HRP20210720T1 (el)
HU (1) HUE054703T2 (el)
LT (1) LT3544976T (el)
PL (1) PL3544976T3 (el)
PT (2) PT3544976T (el)
RS (1) RS61905B1 (el)
SI (2) SI3848369T1 (el)
SM (1) SMT202100279T1 (el)
TW (2) TWI811800B (el)
UY (1) UY37496A (el)
WO (1) WO2018096170A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
LT3544976T (lt) * 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
PL3544977T3 (pl) * 2016-11-28 2021-11-08 Aicuris Gmbh & Co. Kg Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
MX2020003369A (es) 2017-10-05 2020-07-29 Innovative Molecules Gmbh Enantiomeros de tiazoles sustituidos como compuestos antivirales.
TW202038947A (zh) 2018-11-28 2020-11-01 德商創新分子有限責任公司 在與溶瘤病毒之組合療法中治療癌症的解旋酶引子酶抑制劑
CA3168721A1 (en) * 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate
EP3925595A1 (en) * 2020-06-17 2021-12-22 AiCuris GmbH & Co. KG Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl] acetamide hemihydrate
EP4581031A1 (en) 2022-08-29 2025-07-09 Assembly Biosciences, Inc. A novel crystalline form of pritelivir
JP2025527942A (ja) 2022-08-29 2025-08-25 アセンブリー・バイオサイエンシーズ・インコーポレイテッド 新規な結晶形態

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496820A (en) * 1988-10-20 1996-03-05 Peraelampi; Markku Ophthalmic use of S-timolol hemihydrate
DOP2000000109A (es) * 1999-12-23 2002-08-30 Gerald Kleymann Derivados de tiazolilamida
DE10129714A1 (de) 2001-06-22 2003-01-02 Bayer Ag Topische Anwendung von Thiazolylamiden
DE102005014248A1 (de) * 2005-03-30 2006-10-05 Aicuris Gmbh & Co. Kg Pharmazeutische Zubereitung von N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamid
EP2573086A1 (en) * 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(Aminosulfonyl)-4-methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl]acetamide mesylate monohydrate
EP2573085A1 (en) 2011-09-26 2013-03-27 AiCuris GmbH & Co. KG N-[5-(aminosulfonyl)-4methyl-1,3-thiazol-2-yl]-N-methyl-2-[4-(2-pyridinyl)phenyl] acetamide mesylate monohydrate having a specific particle size distribution range and a specific surface area range
LT3544976T (lt) * 2016-11-28 2021-08-10 Aicuris Gmbh & Co. Kg N-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil)-fenil]-acetamido laisvos bazės hemihidratas, jo gamybos būdai ir panaudojimai
PL3544977T3 (pl) * 2016-11-28 2021-11-08 Aicuris Gmbh & Co. Kg Sól maleinianowa wolnej zasady n-[5-(aminosulfonylo)-4-metylo-1,3-tiazol-2-ilo]-n-metylo-2-[4-(2-pirydynylo)fe¬nylo]acetamidu, preparaty farmaceutyczne, sposoby wytwarzania oraz ich zastosowania do leczenia wirusa opryszczki
CA3168721A1 (en) * 2020-03-26 2021-09-30 Jessica Redmer Ophthalmic formulation comprising n-[5-(aminosulfonyl)-4-methyl-1,3- thiazol-2-yl]-n-methyl-2-[4-(2-pyridinyl)phenyl]acetamide hemihydrate

Also Published As

Publication number Publication date
PL3544976T3 (pl) 2021-11-02
EP4201934A1 (en) 2023-06-28
EP3544976B1 (en) 2021-02-17
KR102622289B1 (ko) 2024-01-05
UY37496A (es) 2018-06-29
HUE054703T2 (hu) 2021-09-28
JP2022024043A (ja) 2022-02-08
EP3848369B1 (en) 2023-01-11
WO2018096170A9 (en) 2019-12-19
PT3848369T (pt) 2023-04-10
SMT202100279T1 (it) 2021-07-12
EP3544976A1 (en) 2019-10-02
TWI811800B (zh) 2023-08-11
HRP20210720T1 (hr) 2021-09-03
AU2022263540A1 (en) 2022-12-08
KR102536156B1 (ko) 2023-05-25
AU2017365632B2 (en) 2021-07-15
JP2020509991A (ja) 2020-04-02
WO2018096170A1 (en) 2018-05-31
TWI737861B (zh) 2021-09-01
AU2021221901A1 (en) 2021-09-23
US11021474B2 (en) 2021-06-01
KR20190085115A (ko) 2019-07-17
RS61905B1 (sr) 2021-06-30
PT3544976T (pt) 2021-05-18
CN109996798A (zh) 2019-07-09
AU2017365632A1 (en) 2019-06-13
DK3544976T3 (da) 2021-05-10
DK3848369T3 (da) 2023-03-27
AU2021221901B2 (en) 2022-08-11
CN116804007A (zh) 2023-09-26
CA3045059A1 (en) 2018-05-31
JP6978501B2 (ja) 2021-12-08
US12152022B2 (en) 2024-11-26
EP3848369A1 (en) 2021-07-14
ES2870614T3 (es) 2021-10-27
SI3848369T1 (sl) 2023-07-31
KR20230075524A (ko) 2023-05-31
TW201825483A (zh) 2018-07-16
US20200123145A1 (en) 2020-04-23
CN109996798B (zh) 2023-05-05
SI3544976T1 (sl) 2021-08-31
LT3544976T (lt) 2021-08-10
US20250042893A1 (en) 2025-02-06
ES2941390T3 (es) 2023-05-22
TW202207924A (zh) 2022-03-01
JP7289891B2 (ja) 2023-06-12
US20210269429A1 (en) 2021-09-02
AR110249A1 (es) 2019-03-13

Similar Documents

Publication Publication Date Title
CY1124523T1 (el) Ν-[5-(αμινοσουλφονυλο)-4-μεθυλ-1,3-θειαζολ-2-υλ]-ν-μεθυλ-2-[4-(2-πυριδινυλ)-φαινυλ]-ημιενυδρη ελευθερη βαση ακεταμιδιου, μεθοδοι κατασκευης και χρησεις αυτης
CY1124548T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου του δαγκειου ιου
CY1124855T1 (el) 2-(μορφολιν-4-υλ)-1,7-ναφθυριδινες
CY1122792T1 (el) Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
CY1123604T1 (el) Υδροχλωρικα αλατα ν-(κυανομεθυλ)-4-(2-(4-μορφολινοφαινυλαμινο)πυριμιδιν-4-υλ)βενζαμιδιου
IL282240A (en) Inhibitors of human immunodeficiency virus replication
CY1119066T1 (el) Αναστολεις κρυσταλλικης βρωμο-περιοχης
CR20170411A (es) Composiciones farmacéuticas que comprenden n-(3,5-dimetoxifenil)-n-(1-metiletil)-n-[3-(1-metil-1h-pirazol-4-il-quin oxalin-6-il]etano-1,2-diamina
MX377523B (es) Metodos y composiciones farmaceuticas para el tratamiento de la infeccion por el virus de la hepatitis b.
MX2022009352A (es) Sal de hemisulfato de nucleotido para el tratamiento del virus de hepatitis c.
CL2022000531A1 (es) Composiciones y métodos para el tratamiento de infecciones virales.
EA201690687A1 (ru) Ингибиторы репликации вируса иммунодефицита
CL2016000866A1 (es) Forma salina de hidrocloruro para la inhibición de ezh2
EA201691554A1 (ru) 4'-дифторметилзамещенные производные нуклеозидов в качестве ингибиторов репликации рнк вируса гриппа
CL2016001918A1 (es) Heteroaril amidas como inhibidores de agregación de proteína
AR111469A1 (es) Sal de un compuesto del derivado de aminopiridina, una forma cristalina de la misma, y un proceso para preparar la misma
CL2014000149A1 (es) Metodo para sintetizar n-[5-(aminosulfonil)-4-metil-1,3-tiazol-2-il]-n-metil-2-[4-(2-piridinil) fenil)]acetamida y mesilato monohidrato cristalino del mismo; composicion farmaceutica que lo contiene; combinacion farmaceutica; uso en el tratamiento y/o profilaxis de una infeccion por virus herpes simplex.
CL2014001599A1 (es) Compuestos derivados de nucleosidos sustituidos en 4’-azido, 3’-fluoro o sus sales, como inhibidores de la replicacion del rna del vhc; composicion farmaceutica que los comprende; y su uso para el tratamiento o la profilaxis de la infeccion por el virus de la hepatitis c (vhc).
MX2014005342A (es) Inhibidores del virus de la hepatitis c.
EA201892246A1 (ru) Производные аминотиазола, полученные в качестве противовирусных средств
CY1122882T1 (el) Παραγωγα 3-(καρβοξυαιθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου
CL2017000014A1 (es) Derivados de isondolina para su uso en el tratamiento de una infección viral
MX2018014298A (es) Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida.
CY1122892T1 (el) Παραγωγα 3-(καρβοξυμεθυλ)-8-αμινο-2-οξο-1,3-διαζα-σπειρο-[4.5]-δεκανιου